For the Inventor, By the Inventor

Enter inventor name

Washington, DC, United States of America

Kathleen E Clarence-Smith

USPTO Granted Patents = 32 (Patent Applications = 32)

CIPO Patents = 6 (Patent Applications = 19)

EPO Patents = 6 (Patent Applications = 34)

Average Co-Inventor Count = 1.7

ph-index = 4

Forward Citations = 87(Granted Patents)

Company Filing History:

Chase Pharmaceuticals Corporation

Chase Therapeutics Corporation

Avion Pharmaceuticals, LLC

Chase Parmaceuticals Corporation

Prestwick Pharmaceuticals, Inc.

7. 1 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Loading Chart...

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12390454 - Use and composition for protection against organophosphorus poisoning (2025-08-19),

2. 11896582 - Use and composition for treating myasthenia gravis and other myasthenic syndromes (2024-02-13),

3. 11819485 - Levodopa fractionated dose composition and use (2023-11-21),

4. 11813248 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

5. 11813247 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

6. 11752141 - Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis (2023-09-12),

7. 11547700 - Compositions and methods for treating synucleinopathies (2023-01-10),

8. 11439630 - Use and composition for protection against organophosphorus poisoning (2022-09-13),

9. 11439613 - Levodopa fractionated dose composition and use (2022-09-13),

10. 11389420 - Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis (2022-07-19),

11. 11318122 - Pharmaceutical combination and its use for treating synucleinopathties (2022-05-03),

12. 11266633 - NK-1 antagonist compositions and methods for use in treating depression (2022-03-08),

13. 11160809 - NK1-antagonist combination and method for treating synucleinopathies (2021-11-02),

14. 11033521 - Levodopa fractionated dose composition and use (2021-06-15),

15. 10842778 - Use and composition for treating myasthenia gravis and other myasthenic syndromes (2020-11-24),

Title: The Innovative Mind of Kathleen E Clarence-Smith

Introduction: Kathleen E Clarence-Smith is a pioneering inventor based in Washington, DC. Her groundbreaking work has significantly impacted various industries and technologies.

Latest Patents: Kathleen E Clarence-Smith holds several patents in the fields of renewable energy, sustainable materials, and medical devices. Her most recent patents focus on advancements in clean energy production and eco-friendly materials.

Career Highlights: With a career spanning over two decades, Kathleen E Clarence-Smith has established herself as a leading figure in the innovation landscape. She has worked with top research institutions and companies to bring her ideas to life.

Collaborations: Throughout her career, Kathleen E Clarence-Smith has collaborated with renowned scientists, engineers, and designers to push the boundaries of technology. Her ability to work across disciplines has led to the development of cutting-edge solutions.

Conclusion: Kathleen E Clarence-Smith's dedication to innovation and her passion for creating a sustainable future make her a true trailblazer in the world of inventions. Her work continues to inspire the next generation of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…